Cantor Fitzgerald Slashes PT on Oncothyreon (ONTY) from $11 to $4

Article Related Press Releases (1) Related Articles (1) Stock Quotes (2) Comments (0)

Cantor Fitzgerald today maintained a Buy rating on Oncothyreon (NASDAQ: ONTY) and cut its price target to $4.00 (from $11.00). The cut in price target relates to the loss of candidate Stimuvax (L-BLP25).

"While partner Merck (NYSE: MRK) KGaA has indicated that treatment effects were observed in sub-populations, and an abstract has been submitted to ASCO for this year, our financial model assumes that commercialization does not occur and no value for this candidate is included in our valuation," said analyst Adeyemi Ogunkoya.

For an analyst ratings summary and ratings history on Oncothyreon (NASDAQ: ONTY) click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $2.21 yesterday, with a 52 week range of $1.71-$6.24.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Benchmark Boosts PT on R.R. Donnelley (RRD)
• Leerink Swann Bullish on Insmed (INSM); Raises PT to $22
• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?